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SCCA1Psoriasis is a chronic inﬂammatory skin diseasewith unknown aetiology. Inﬁltration of inﬂammatory cells as the
initial event in the development of newpsoriatic plaques togetherwith the deﬁned inﬂamedareas of such lesions
argues for an immunological disease with a local production of a causal antigen. The auto-antigen Pso p27 is a
protein expressed in the skin lesions. We recently demonstrated that Pso p27 is homologous to the core amino
acid sequences of squamous cell carcinoma antigens 1 and 2 (SCCA1/2) and it is apparently generated from
SCCAmolecules bydigestionwith highly speciﬁc endoproteases. In this communicationwe demonstrate the gen-
eration of Pso p27 from SCCA1 with extracts from psoriatic scale and even more remarkably, the generation of
Pso p27 from SCCA1 in the presence ofmast cell associated chymase. These ﬁndings open up for new therapeutic
strategies in psoriasis and probably also in other autoimmune diseases as Pso p27 epitopes have been detected in
diseased tissues from patients with various chronic inﬂammatory diseases.
© 2014 The Authors. Published by Elsevier B.V.Open access under CC BY license.1. Introduction
Psoriasis is a chronic inﬂammatory skin disease which afﬂicts about
2% of the general population. The association between psoriasis and
selected MHC molecules and the deﬁned skin lesions argues for an
immunologic disease caused by a speciﬁc and locally expressed anti-
gen [1,2].
Pso p27 is a protein detected in mast cells in psoriatic lesions and
extractable from psoriatic scale, while it is not present in uninvolved
psoriatic skin or skin from healthy controls [3–5]. The presence of
speciﬁc antibodies against Pso p27 in psoriatic scale makes Pso p27 a
candidate as causal agent in the immune reactions in psoriasis [4].
Sequencing of Pso p27 has demonstrated homologies with squamous
cell carcinoma antigens (SCCAs). This includes conformities with
SCCA1 (serpin B3) as well as SCCA2 (serpin B4) [6]. Pso p27 is a smaller
protein compared to SCCA molecules, and analyses have shown that
the N-terminal and the C-terminal ends of the SCCA molecules are not
present in Pso p27. Based on this knowledge we suggested that Pso
p27 is generated by posttranslational modiﬁcation of the SCCA mole-
cules [6]. This was substantiated through indirect immunoﬂuorescence
analysis of skin biopsies from psoriatic patients using speciﬁc antiserum
against theN-terminal end of SCCA1 and speciﬁcmonoclonal antibodies
against Pso p27 [7]. These observations give rise to the assumption thatence and Technology, Faculty of
and Women's Health, Postbox
fax: +47 72576416.
.Open access under CC BY license.Pso p27 is generated from the SCCAmolecules in dermal cells and at the
surface of the epidermis.
In this communication we demonstrate the generation of Pso p27
from recombinant SCCA1 by speciﬁc endoproteolytic activity in extracts
from psoriatic scale and with mast cell associated chymase.
2. Materials and methods
2.1. Indirect immune ﬂuorescence of biopsies obtained from psoriatic skin
lesions
Skin punch biopsies were taken from psoriatic lesions and snap fro-
zen in liquid nitrogen. Thin sections from the biopsies were cut and
stored at−80 °C. Prior to indirect immunoﬂuorescence analysis the sec-
tionswere air dried at room temperature andﬁxed for 15min in acetone.
The sections were incubatedwith rabbit polyclonal anti-SCCA antiserum
(ab47726 Abcam), 20 μg/ml and biotinylated mouse monoclonal
anti-Pso p27 antibody (3A3D10), 8 μg/ml [8,9], diluted in phosphate
buffered saline containing 0.05% Tween 20 (PBS-T). After washing
with PBS-T the sections were incubated with ﬂuorescein isothiocya-
nate conjugated swine anti-rabbit antibodies (DAKO) and Molecular
Probes® Streptavidin-conjugated Alexa 594 (Invitrogen Life Science).
After thorough washing with PBS-T the sections were mounted with
Vectashield Mounting Medium H-1000 (Vector Laboratories).
2.2. Expression and puriﬁcation of recombinant SCCA1
The construct pMCSG7 serpin B3 (Clone ID: HsCD00343153) was
purchased from “DNASU plasmid repository” at the Biodesign Institute/
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in Escherichia coli BL21 (DE3) RIPL (Stratagene). The bacterial pellet
was resuspended in 50 mM Na2PO4, 300 mM NaCl, 10 mM imidazole,
and 10 mM β-mercaptoethanol pH 8 and lysed by sonication on ice.
Expressed proteins were puriﬁed using Talon superﬂow metal afﬁnity
resin (Clontech). Fractions containing His-SCCA1were buffer exchanged
using Amicon Ultra centrifugal ﬁlters (Millipore) with a molecular cutoff
of 10 kDa. The protein was further puriﬁed using HiTrapQ (GE
Healthcare) and a 20 min gradient from 20 mM Tris–HCl pH 8, 20 mM
NaCl to 20 mM Tris–HCl pH 8, and 0.5 M NaCl. Fractions containing
pure SCCA1 were pooled, snap-frozen in liquid nitrogen and stored at
−80 °C.2.3. Preparation of scale extract and generation of Pso p27 from
recombinant SCCA1
Psoriatic scale (300 mg) was homogenized in 10 ml PBS by using an
UltraTurrax T25 (Rose Scientiﬁc Ltd.). The crude extract was centrifuged
at 16,000 ×g for 10 min and 1 ml of the supernatant was applied on
CnBr-act Sepharose 4B (AmershamBiosciences) coupledwithmonoclo-
nal anti-Pso p27 antibodies. The extract was repeatedly passed through
the immunosorbent column for elimination of the majority of Pso p27
present in the scale extract. The ﬁnal efﬂuent was used for enzymatic
digestion. Digestion was performed in PBS at 37 °C and the reaction
mixture contained efﬂuent corresponding to scale extract diluted 1/
800 and 1 μg/ml recombinant SCCA1. Quantiﬁcation of Pso p27 antigenA B
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Fig. 1. (A and B) SCCA1 and Pso p27 are spatially separated in psoriatic skin. Double labelling o
(C) ELISA quantiﬁcation of Pso p27 antigen formed by incubation of SCCA1 with psoriatic scale
respectively. (D) SDS-PAGEdemonstrating intermediate proteolytic fragments of SCCA1. Lane 1;
extract, lane 4; SCCA1 incubated with Pso p27-depleted psoriatic scale extract.was performed by sandwich-ELISA using speciﬁc mouse monoclonal
antibodies against Pso p27 [10].
2.4. Incubation of recombinant SCCA1 with psoriatic scale extract (Fig. 1D)
The following samples were incubated for 3 days at 37 °C:
a) Recombinant SCCA1
b) Pso p27 depleted scale extract diluted 1/800
c) Recombinant SCCA1 and Pso p27 depleted scale extract diluted
1:800.
2.5. Incubation of recombinant SCCA1 with recombinant chymase and
tryptase (Fig. 2C)
The following samples were incubated for 3 days at 37 °C:
a) Recombinant SCCA1andhuman recombinant tryptase (MyBioSource),
w/w ratio 100:1
b) Recombinant SCCA1 and human recombinant chymase (Sigma-
Aldrich) w/w ratio 100:1
c) Recombinant SCCA1.
2.6. Gel-electrophoretic analyses
The samples were analysed with SDS-polyacrylamide gel electro-
phoresis (SDS-PAGE) by running 4–12% NuPage Novex Bis–TrisIntact SCCA1
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f a thin section of a psoriatic plaque detecting SCCA1 antigen (A) and Pso p27 antigen (B).
extract. Recombinant SCCA1 and scale extract was incubated at 37 °C for 0, 1, 4 and 18 h,
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Fig. 2. (A and B) SCCA1 and Pso p27 are present in the same dermal cells in psoriatic skin. Double labelling of a thin section of a psoriatic plaque detecting SCCA1 antigen (A) and Pso p27
antigen (B). (C) SDS-PAGE demonstrating the digestion of recombinant SCCA1 in the presence of chymase. Lane 1; protein MW standard, lane 2; recombinant SCCA1+ tryptase, lane 3;
recombinant SCCA1 + chymase and lane 4; recombinant SCCA1.
736 H. Lysvand et al. / Biochimica et Biophysica Acta 1842 (2014) 734–738acrylamide gels in MOPS running buffer (Novex by Life Technologies).
The gels were stained with Simply Blue Safe Stain (Novex by Life
Technologies).
2.7. MALDI MS/MS analysis of excised protein bands
The protein bands containing about 1 μg protein were excised and
in-gel digested [11] with Sequence Grade Modiﬁed Trypsin (Promega),
Endoproteinase Lys-C (Sigma) or Endoproteinase Glu-C (New England
Biolabs). The peptides were further extracted from the gel and desalted
using Stage Tip puriﬁcation [12]. The puriﬁed peptidesweremixedwith
an equal volume of 10 mg/ml 2,5-dihydroxybenzoic acid (DHB), air
dried on a stainless steel sample stage and analysed on an Ultraﬂex III
TOF/TOF (Bruker Daltonics) mass spectrometer.
3. Results
3.1. Generation of antigen Pso p27 from recombinant SCCA1 with scale
extracts
Indirect immunoﬂuorescence of psoriatic skin lesions using a rabbit
antiserum against the N-terminal end of the SCCA and a speciﬁc mono-
clonal antibody against Pso p27 is shown in Fig. 1. A strong green
ﬂuorescence representing the SCCAmolecules was observed in the epi-
dermis with a markedly weaker signal in epidermal cells close to the
surface (Fig. 1A). Conversely, a strong red ﬂuorescence representing
Pso p27 was observed in the epidermal cells close to the surface and
the scale whereas this signal was markedly weaker in the deeper layer
(Fig. 1B).
Themarkedly differential localization of the SCCA and Pso p27 in the
epidermal compartments suggested the presence of an endoproteolytic
SCCA-targeting factor at the skin surface layer. To investigate this
further we set up a quantitative ELISA-based cleavage assay to monitor
potential conversion of puriﬁed, recombinant SCCA1 to Pso p27 by incu-
bation with extract from psoriatic scale.
The puriﬁed SCCA1 protein was not recognized by the monoclonal
anti-Pso p27 antibodies (Fig. 1C, time 0). When SCCA1 was incubated
with Pso p27-depleted psoriatic scale extract the sandwich ELISA dem-
onstrated signiﬁcant generation of Pso p27 antigen and that the amount
of Pso p27 increased with prolonged incubation times (Fig. 1C).
To further study if the generation of Pso p27was a result of enzymat-
ic digestion of SCCA1 with speciﬁc endoproteases, the digested SCCA1
was analysed by SDS-PAGE. As demonstrated in Fig. 1D, no cleavage
products of SCCA1 were observed in the puriﬁed SCCA1 substrate
(Fig. 1D, lane 2). Moreover, neither intact SCCA1 nor cleavage productswere observed in Pso p27-depleted scale extract (Fig. 1D, lane 3). 3
novel forms of SCCA1 with increased electrophoretic migration were
observed after 18 h of incubationwith scale extract, with a concomitant
reduction of intact SCCA1 (Fig. 1D, lane 4). MALDI MS/MS mass
spectrometry analysis of the 3 novel forms identiﬁed them to be
C-terminally truncated SCCA1 (fragment 1), N-terminally truncated
SCCA1 (fragment 2) and both C- and N-terminally truncated forms of
SCCA1 (fragment 3), corresponding to the Pso p27 protein.
3.2. Generation of Pso p27 from recombinant SCCA1 with chymase
The concomitant presence of SCCA1 and Pso p27 in the same cells
indicated an intracellular generation of Pso p27 (Fig. 2A and B). As
these cells have been shown to bemast cells [7], themast cell associated
endoproteases, tryptase and chymase, were potential candidates for the
transformation. SDS-PAGE analysis of recombinant SCCA1 after incuba-
tionwith tryptase and chymase, respectively, is demonstrated in Fig. 2C.
The SCCA1 molecules were digested in the presence of chymase to a
fragment with the same apparent molecular mass as fragment 3 in
Fig. 1D.
MS analyses of this new fragment showed N-terminal and C-
terminal ends in accordance with those described for Pso p27 [6] and
fragment 3 obtained when recombinant SCCA1 was incubated with
scale extract (Fig. 1D).
3.3. Conformational consequences when Pso p27 is generated from SCCA1
TheN- and C-terminal cleavage points of the SCCA at Tyr73/His74 and
Val349/Val350 (Fig. 3A) both reside in regions of the SCCA crystal struc-
ture that have weak electron density [13] and that likely constitute
ﬂexible loop regions at the protein surface. The N-terminal fragment
of 73 residues contain three α-helices of which α1 and α2 reside at
the junction between beta-sheet A (βA) and beta-sheet B (βB) and ren-
der (βB) solvent exposed (Fig. 3B). Additional removal of the C-terminal
41 residueswould eliminate two strands of beta-sheet B as well asmost
of the reactive centre loop (RCL) that is essential for cysteine protease
inhibition [14] as well as for inhibition of the JNK1 kinase activity [13].
A hypothetical 3-dimensional model of Pso p27 based on the SCCA1
crystal structure (PDB ID: 2ZV6) is presented in Fig. 3B. However, it is
very likely that removal of the N- and C-terminal fragments of SCCA1
is accompanied by pronounced structural destabilization of the core
(Pso p27) region of the protein. Further work to investigate the struc-
tural implications associated with proteolytic cleavage of SCCA1 is
now in progress in our laboratory.
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Fig. 3. (A). Schematic illustration of the cleavage products of SCCA1as determined by MALDI MS/MS analyses. (B) Crystal structure of intact SCCA1 [13] (PDB ID: 2ZV6). Arrows indicate
the C-terminal and N-terminal (within the RSL) cleavage points (upper panel) aswell as the three serpin-typicβ-sheets and the reactive centre loop (RCL). The lower panelmodels SCCA1
74-349 lacking both the N- and C-terminal fragments and corresponding to fragment 3 (Pso p27) (based on PDB ID: 2ZV6).
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Much effort has been put forward in the search for etiological agents
associatedwith chronic inﬂammatory— or autoimmunediseases. Psori-
asis is a chronic inﬂammatory skin disease which shares many of the
features of other autoimmune diseases. The typical psoriatic plaques
have well deﬁned boundaries with the surrounding skin. The chronicity
of these inﬂamed lesions argues for a local generation of an auto-
antigen. During the last decades we have focused on a protein, Pso
p27, associated with psoriasis [4,5,8]. Pso p27 is expressed in psoriatic
lesions and is not detected in uninvolved psoriatic skin or skin biopsies
from healthy controls [5,8,9]. Through analysis of antibodies obtained
from psoriatic scale, we have demonstrated the potential role of Pso
p27 as an auto-antigen in psoriasis [3,4].
Based on sequence homologies between Pso p27 and the SCCA
proteins we have hypothesized that Pso p27 is generated by post-
translational modiﬁcations of the SCCA molecules [6]. The concurrent
presence of the SCCA and Pso p27 in dermal cells in psoriatic lesions
substantiates the assumption of a posttranslational generation of Pso
p27 from the SCCA [7].
In this communication we demonstrate that Pso p27 is generated
from recombinant SCCA1 when incubated with extracts from psoriatic
scale. Interestingly, the proteolytic processing generates two distinct
intermediate fragments, omitting either the N-terminal end or the
C-terminal end. This strongly suggests that the two digestions are not
sequential (Fig. 1D).
Overexpression of SCCA1 in epidermal cells in psoriatic lesions has
been described earlier [15] but the expression of the SCCA molecules
in Pso p27 positive dermal cells is probably of greater signiﬁcance
with respect to psoriasis pathogenesis [7]. The concomitant presence
of SCCA1 and Pso p27 in the same cells indicates an intracellular gener-
ation of Pso p27 (Fig. 2A and B). As these cells are shown to bemast cells
[5], the mast cell associated endoproteases, tryptase and chymase, are
potential candidates for the transformation. The SCCA1 molecules
digested in the presence of chymase gave a fragment with the sameapparent molecular mass as fragment 3 in Fig. 1D, and MS analyses
of this new fragment showed that N-terminal and C-terminal ends are
in accordance with those described for Pso p27 [6]. The suggestion of
mast cells as antigen presenting cells [16] and the well documented
association between psoriasis and selected MHC-I molecules together
make the observations described particularly challenging.
The immunological reaction with the Pso p27 speciﬁc monoclonal
antibodies implies that the N- and/or C-terminal regions in the native
SCCA may mediate steric obstruction of the antibody-binding epitopes
as indicated in the crystallographic structure and model presented in
Fig. 3B. Alternatively, removal of these termini may alter the conforma-
tion of the core region of SCCA1 to be recognized by the antibodies.
It has previously been shown that incubation of SCCA1 with papain-
like cysteine protease results in cleavage in the RCL loop between Gly353
and Ser 354, which is four residues away from the cleavage site induced
by psoriatic scale extract. Although cleavage within the RCL would
imply partial disruption of two of the three β-sheets in the SCCA1 struc-
ture, this cleavage did not result in any apparent conformational change
of the major cleavage product as determined from circular dichroism
analysis [13]. The N-terminal cleavage between Tyr73 and His74 report-
ed here results in loss of the α1–3 helices that are shielding the third
β-sheets from solvent exposure. It is likely that removal of both the
N- and C-terminal regions would result in signiﬁcant alteration in the
overall structure of the resulting fragment 3 (Pso p27), but the answer
to this must await structural analysis of the Pso p27 protein.
Nevertheless, if we assume that the proteolytic modiﬁcation of the
SCCA molecules is a premise for the antigenicity of Pso p27, a potential
therapeutic strategy would be inhibition of the proteolysis. Pso p27 an-
tigen has been shown to participate in the generation of complement
activating immune complexes, both in the psoriatic plaques and in
synovial ﬂuid from patients with psoriasis arthritis [3,17]. Moreover,
Pso p27 antigen has been detected in patients with various inﬂammato-
ry diseases as for example ankylosing spondylitis [17], sarcoidosis [10]
and chronic inﬂammatory bowel diseases [18]. The proteolytic genera-
tion of Pso p27 described heremay thus pave theway for new strategies
738 H. Lysvand et al. / Biochimica et Biophysica Acta 1842 (2014) 734–738with respect to search for therapeutic agents against psoriasis and other
autoimmune diseases where Pso p27may play a crucial role [10,17,18].
5. Conclusion
The auto-antigen Pso p27 is generated from SCCA molecules with
speciﬁc endoproteolytic activity in psoriatic lesions. These ﬁndings
open up for new therapeutic strategies in psoriasis and probably also
in other autoimmune diseases as Pso p27 epitopes have been detected
in diseased tissues from patients with various chronic inﬂammatory
diseases.
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